Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
30 Novembro 2023 - 6:05PM
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN)
will host a conference call and simultaneous webcast to provide an
update on the company's hematology portfolio on Thursday, December
14, 2023 at 8:30 AM ET. This investor call follows Regeneron data
updates presented at the 65th American Society of Hematology (ASH)
Annual Meeting and Exposition, from December 9-12, 2023.
The webcast may be accessed from the "Investors
& Media" page of Regeneron's website at
https://investor.regeneron.com/events-and-presentations. To
participate via telephone, please register in advance at this link.
Upon registration, all telephone participants will receive a
confirmation email detailing how to join the conference call,
including the dial-in number along with a unique passcode and
registrant ID that can be used to access the call. A replay and
transcript of the webcast will be archived on the Company's website
for at least 30 days.
About Regeneron Regeneron is a
leading biotechnology company that invents, develops, and
commercializes life-transforming medicines for people with serious
diseases. Founded and led for 35 years by physician-scientists,
Regeneron's unique ability to repeatedly and consistently translate
science into medicine has led to numerous FDA-approved treatments
and product candidates in development, almost all of which were
homegrown in Regeneron's laboratories. Regeneron's medicines and
pipeline are designed to help patients with eye diseases, allergic
and inflammatory diseases, cancer, cardiovascular and metabolic
diseases, hematologic conditions, infectious diseases, and
rare diseases.
Regeneron is accelerating and improving the
traditional drug development process through its
proprietary VelociSuite® technologies, such
as VelocImmune®, which uses unique genetically
humanized mice to produce optimized fully
human antibodies and bispecific antibodies, and through
ambitious research initiatives such as the Regeneron Genetics
Center®, which is conducting one of the largest genetics sequencing
efforts in the world.
For additional information about Regeneron, please
visit www.regeneron.com or follow Regeneron on
LinkedIn.
Contact Information: Investor
Relations Ryan Crowe 914.847.8790 ryan.crowe@regeneron.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024